1. Home
  2. CDT vs PRPO Comparison

CDT vs PRPO Comparison

Compare CDT & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDT
  • PRPO
  • Stock Information
  • Founded
  • CDT 2019
  • PRPO N/A
  • Country
  • CDT United States
  • PRPO United States
  • Employees
  • CDT 7
  • PRPO N/A
  • Industry
  • CDT Biotechnology: Pharmaceutical Preparations
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • CDT Health Care
  • PRPO Industrials
  • Exchange
  • CDT Nasdaq
  • PRPO Nasdaq
  • Market Cap
  • CDT 9.0M
  • PRPO 8.8M
  • IPO Year
  • CDT N/A
  • PRPO N/A
  • Fundamental
  • Price
  • CDT $0.07
  • PRPO $5.27
  • Analyst Decision
  • CDT
  • PRPO
  • Analyst Count
  • CDT 0
  • PRPO 0
  • Target Price
  • CDT N/A
  • PRPO N/A
  • AVG Volume (30 Days)
  • CDT 16.2M
  • PRPO 5.8K
  • Earning Date
  • CDT 02-14-2025
  • PRPO 11-06-2024
  • Dividend Yield
  • CDT N/A
  • PRPO N/A
  • EPS Growth
  • CDT N/A
  • PRPO N/A
  • EPS
  • CDT N/A
  • PRPO N/A
  • Revenue
  • CDT N/A
  • PRPO $17,411,000.00
  • Revenue This Year
  • CDT N/A
  • PRPO $75.18
  • Revenue Next Year
  • CDT N/A
  • PRPO N/A
  • P/E Ratio
  • CDT N/A
  • PRPO N/A
  • Revenue Growth
  • CDT N/A
  • PRPO 31.31
  • 52 Week Low
  • CDT $0.06
  • PRPO $4.31
  • 52 Week High
  • CDT $5.44
  • PRPO $7.30
  • Technical
  • Relative Strength Index (RSI)
  • CDT 40.15
  • PRPO 32.33
  • Support Level
  • CDT $0.08
  • PRPO $5.72
  • Resistance Level
  • CDT $0.09
  • PRPO $6.48
  • Average True Range (ATR)
  • CDT 0.01
  • PRPO 0.24
  • MACD
  • CDT -0.00
  • PRPO -0.05
  • Stochastic Oscillator
  • CDT 27.18
  • PRPO 3.98

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Share on Social Networks: